Literature DB >> 20951913

Current medical treatments of dyspepsia and irritable bowel syndrome.

Michael Camilleri1, Jan F Tack.   

Abstract

Dyspepsia is a highly prevalent condition characterized by symptoms originating in the gastroduodenal region without underlying organic disorder. Treatment modalities include acid-suppressive drugs, gastroprokinetic drugs, Helicobacter pylori eradication therapy, tricyclic antidepressants, and psychological therapies. Irritable bowel syndrome is a multifactorial, lower functional gastrointestinal disorder involving disturbances of the brain-gut axis. The pathophysiology provides the basis for pharmacotherapy: abnormal gastrointestinal motor functions, visceral hypersensitivity, psychosocial factors, intraluminal changes, and mucosal immune activation. Medications targeting chronic constipation or diarrhea may also relieve irritable bowel syndrome. Novel approaches to treatment require approval, and promising agents are guanylate cyclase cagonists, atypical benzodiazepines, antibiotics, immune modulators, and probiotics.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951913     DOI: 10.1016/j.gtc.2010.08.005

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  11 in total

1.  Carboxy terminus of heat shock protein (HSP) 70-interacting protein (CHIP) inhibits HSP70 in the heart.

Authors:  Bijun Zhao; Guocheng Sun; Guanli Feng; Weixun Duan; Xiaoling Zhu; Shaoyang Chen; Lichao Hou; Zhenxiao Jin; Dinghua Yi
Journal:  J Physiol Biochem       Date:  2012-03-29       Impact factor: 4.158

2.  Effect of electro-acupuncture at different acupoints on neuropeptide and somatostatin in rat brain with irritable bowel syndrome.

Authors:  Wen-Lian Zhu; Ying Li; Hui-Fang Wei; Xiao-Xuan Ren; Jie Sun; Lu-Fen Zhang; Jiang Zhu
Journal:  Chin J Integr Med       Date:  2012-03-30       Impact factor: 1.978

3.  Mangiferin, a natural xanthone, accelerates gastrointestinal transit in mice involving cholinergic mechanism.

Authors:  Talita Cavalcante Morais; Synara Cavalcante Lopes; Karine Maria Martins Bezerra Carvalho; Bruno Rodrigues Arruda; Francisco Thiago Correia de Souza; Maria Teresa Salles Trevisan; Vietla Satyanarayana Rao; Flávia Almeida Santos
Journal:  World J Gastroenterol       Date:  2012-07-07       Impact factor: 5.742

Review 4.  Current management strategies and emerging treatments for functional dyspepsia.

Authors:  Michael Camilleri; Vincenzo Stanghellini
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-05       Impact factor: 46.802

Review 5.  Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.

Authors:  Khaled A Jadallah; Susan M Kullab; David S Sanders
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

6.  Effect of amitriptyline on gastrointestinal function and brain-gut peptides: a double-blind trial.

Authors:  Wei Huang; Shu-Man Jiang; Lin Jia; Le-Qing You; Yao-Xing Huang; Yan-Mei Gong; Gui-Qin Wang
Journal:  World J Gastroenterol       Date:  2013-07-14       Impact factor: 5.742

7.  Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation.

Authors:  Maura Corsetti; Jan Tack
Journal:  United European Gastroenterol J       Date:  2013-02       Impact factor: 4.623

Review 8.  Current management of functional dyspepsia: impact of Rome III subdivision.

Authors:  Georgios P Karamanolis; Jan Tack
Journal:  Ann Gastroenterol       Date:  2012

9.  Overlap in patients with dyspepsia/functional dyspepsia.

Authors:  Yasuhiro Fujiwara; Tetsuo Arakawa
Journal:  J Neurogastroenterol Motil       Date:  2014-09-26       Impact factor: 4.924

10.  Efficacy of prebiotics and probiotics for functional dyspepsia: A systematic review and meta-analysis.

Authors:  Jiaqi Zhang; Hao Meng Wu; Xue Wang; Jingyi Xie; Xia Li; Jinxin Ma; Fengyun Wang; Xudong Tang
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.